Levels Dx currently has three projects under development. The first project focuses on early diagnosis of the most common type of liver cancer: hepatocellular carcinoma (HCC). Together with the Leiden University Medical Center (LUMC), Levels Dx identified a combination of biomarkers that can detect early-stage HCC with more accuracy than the current clinical standard. To further validate these biomarkers, the company is working on the organization of new clinical trials with larger patient cohorts.
Copyright © Alle rechten voorbehouden